Welcome to our dedicated page for Wave Life Scienc SEC filings (Ticker: WVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wave Life Sciences Ltd. (Nasdaq: WVE) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed through EDGAR. Wave is a clinical-stage biotechnology company incorporated in Singapore with ordinary shares listed on The Nasdaq Global Market, and it uses SEC filings to report material events, financial results, securities offerings, and corporate actions.
Recent WVE SEC filings include multiple Forms 8-K describing public offerings of ordinary shares and pre-funded warrants under an automatically effective shelf registration statement on Form S-3ASR, along with related underwriting agreements and legal opinions. Other 8-K filings furnish press releases covering quarterly financial results, clinical data updates for programs such as WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency, and corporate presentations made available to investors.
Wave also files 8-Ks to report shareholder meeting outcomes and compensation-related matters, such as amendments to its equity incentive plan and voting results from its annual general meeting. Many of these filings specify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act and indicate when press releases or slide decks are incorporated by reference.
On Stock Titan, these filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand items like new securities offerings, changes to compensation plans, or important clinical and financial announcements referenced in 8-Ks. Users can review filing titles, dates, and summarized content, then open the full SEC documents for detailed analysis of Wave Life Sciences’ regulatory and disclosure history.
Wave Life Sciences Ltd. director reports option exercise and share sale. On December 8, 2025, director Adrian Rawcliffe exercised 42,000 share options for Wave Life Sciences ordinary shares at an exercise price of $5.97 per share. On the same day, he sold 42,000 ordinary shares at a sale price of $15.00 per share.
Following these transactions, Rawcliffe directly held 12,700 ordinary shares and no remaining share options. The filing states that the option exercise and related sales were carried out under a Rule 10b5-1 trading plan adopted on August 5, 2025, which is a pre-arranged plan intended to allow insiders to trade on a scheduled basis.
Wave Life Sciences Ltd. director reported stock transactions in company ordinary shares. On 12/08/2025, the insider exercised share options with an exercise price of $5.97 per share and sold 7,000 shares at $13 and another 7,000 shares at $14.
After these transactions, the reporting person directly owned 44,930 ordinary shares. The filing also shows share options to buy Wave Life Sciences ordinary shares at $5.97 that are fully vested and were transacted under a Rule 10b5-1 trading plan adopted on March 13, 2025.
Wave Life Sciences Ltd. director Gregory L. Verdine reported sales of company stock. On 12/08/2025, he sold 12,020 ordinary shares at a weighted-average price of $13.09 per share and 7,980 ordinary shares at a weighted-average price of $14.05 per share.
The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025. After these transactions, Verdine directly owned 275,217 ordinary shares of Wave Life Sciences. The price ranges for the sales were $12.75–$13.74 and $13.75–$14.70 per share, respectively.
Wave Life Sciences Ltd. executive reports option exercises and share sales. On December 8, 2025, a senior officer of Wave Life Sciences exercised multiple vested share options with exercise prices ranging from $2.83 to $10.48 per ordinary share and sold the resulting shares on the same day. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 5, 2025.
Following the reported option exercises and sales, the officer directly holds 25,000 ordinary shares. The filing notes that certain sale prices are reported on a weighted-average basis, including averages of $14.556 and $14.195 per share, and the officer has agreed to provide full pricing details upon request.
Wave Life Sciences Ltd. reported insider transactions by its Chief Financial Officer, Kyle Moran, in a Form 4 filing. On December 8–9, 2025, he exercised multiple share options and sold ordinary shares in the company.
The transactions included option exercises coded "M" and sales coded "S" in several tranches. Reported sales used weighted-average prices around $13.20, $15.00–$15.045, and $20.00–$20.22 per share, with the filing noting that detailed price breakdowns are available on request. These trades were carried out under a Rule 10b5-1 trading plan adopted on March 13, 2025.
After the reported transactions, Moran directly beneficially owned 90,365 ordinary shares of Wave Life Sciences and held several fully vested or scheduled-vesting share options with exercise prices ranging from $2.83 to $10.48 per share and expirations between 2030 and 2033.
Wave Life Sciences Ltd. director Mark Corrigan reported open‑market sales of company ordinary shares under a pre‑arranged Rule 10b5‑1 trading plan. On December 8, 2025, he sold 9,600 ordinary shares at a weighted‑average price of $13.09 per share and later the same day sold an additional 6,515 ordinary shares at a weighted‑average price of $14.065 per share. After these transactions, he beneficially owned 35,330 ordinary shares following the first sale and 28,815 ordinary shares following the second, all held directly. The prices for each block reflect multiple individual trades within stated ranges, and full trade‑level details are available from the reporting person upon request.
Wave Life Sciences Ltd. director Christian Henry reported a series of option exercises and share sales in the company’s ordinary shares. On December 8, 2025, he exercised options to buy 42,000 shares at $5.97, 15,000 shares at $3.50, and 30,000 shares at $4.585 per share, all from fully vested options. He then sold 6,445 shares at $12.75, 42,000 shares at $12.75, 15,000 shares at a weighted-average price of $14.07 (with individual trades between $14.00 and $14.14), and 30,000 shares at a weighted-average price of $18.02 (with trades between $18.00 and $18.19). After these transactions, he directly owned 12,700 ordinary shares and retained options for 6,000 shares at $3.50 and 15,000 shares at $4.585. All trades were made under a Rule 10b5-1 trading plan adopted on August 6, 2025.
Wave Life Sciences Ltd. furnished an updated corporate presentation for the investment community. The new presentation, dated November 17, 2025, provides business updates and is available in the Investors section of the company’s website. It is also included as Exhibit 99.1 and is furnished, not filed, meaning it is not subject to certain Exchange Act liabilities or automatically incorporated into other SEC filings.
Wave Life Sciences Ltd. (WVE) director Adrian Rawcliffe reported an open-market sale of company stock. On 11/13/2025, he sold 16,115 ordinary shares of Wave Life Sciences at a weighted-average price of $6.79 per share, in multiple transactions executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 5, 2025. After this transaction, the reporting person beneficially owned 12,700 ordinary shares, held directly.
The filing notes that the shares were sold in several trades within a price range of $6.64 to $7.00 per share, and the reporting person has undertaken to provide full details of the number of shares sold at each separate price upon request by the issuer, its security holders, or the SEC staff.
Wave Life Sciences (WVE): RA Capital Healthcare Fund, L.P. and affiliated reporting persons disclosed an open-market purchase of 1,000 ordinary shares on 11/13/2025 at a weighted average price of $6.6875. Following the transaction, they reported 18,203,009 shares beneficially owned indirectly. The purchase was made to extend the period for acquisitions under the fund’s Hart-Scott-Rodino filing. Previously reported 28,815 RSUs granted to Dr. Peter Kolchinsky are held for the benefit of the fund.